News and Trends 10 Sep 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front.
Obesity
- Latest Posts
Best in Biotech 5 Sep 2024
Six biotech companies that could revolutionize obesity treatments
In this article, we take a look at six biotechs focused on bringing drugs to treat obesity to the market.
News and Trends 28 Aug 2024
GLP-1 shortage: Can biotech companies keep up with rising demand?
How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question.
In Depth 24 Jul 2024
Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?
Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
In Depth 18 Jan 2024
GLP-1 agonists: what’s the hype about?
GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs.
ADVERTISEMENT
ADVERTISEMENT
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
Best in Biotech 20 Dec 2023
Wrapping up 2023: A recap of top biotech moments of this year
2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023.
Best in Biotech 19 Dec 2023
Nine biotech companies to watch in 2024
2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.
In Depth 28 Sep 2023
Obesity drug success sparks biotech buying spree
The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […]
In Depth 25 Jul 2023
New weight loss drugs: biotech’s mission to end obesity
Obesity has nearly tripled since 1975, becoming an ever-growing health threat. In 2016, it was estimated that more than 1.9 billion adults in the world were overweight, with more than 650 million of those being officially obese. Obesity can be defined as abnormal or excessive fat accumulation that presents a risk to health, with a […]
News and Trends 1 Jun 2023
Fighting obesity with gene therapy
Scientists from the University of Barcelona in Spain and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) have designed a strategy to fight obesity and diabetes in mice through ex vivo gene therapy. The technique consists of implanting cells that have been manipulated and transformed in order to treat a disease. This […]
ADVERTISEMENT
